Thermo Fisher Scientific Inc. announced the completion of its repurchase of $1 billion of its common stock, totaling 1.9 million shares. This action reflects the company's ongoing commitment to its capital deployment strategy.
As of December 3, 2024, following this completion, $3 billion remained available under the company’s existing share repurchase authorization. This indicates a continued capacity and intention to return capital to shareholders.
The completion of this buyback program demonstrates the company's execution on its previously announced capital allocation plans. Share repurchases can enhance shareholder value by reducing the share count and potentially increasing earnings per share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.